



## Drug Targeting for CNS Disease

Guest Editors:

**Dr. Dorota Łażewska**

Chair of Technology and  
Biotechnology of Medical  
Remedies, Faculty of Pharmacy,  
Jagiellonian University Medical  
College in Kraków, Ul. Medyczna  
9, 30-688 Kraków, Poland

**Dr. Anna Stasiak**

Department of Hormone  
Biochemistry, Faculty of  
Medicine, Medical University of  
Lodz, Żeligowskiego 7/9 Str., 90-  
752 Lodz, Poland

Deadline for manuscript  
submissions:

**closed (30 September 2022)**

### Message from the Guest Editors

Dear Colleagues,

Current treatment of CNS diseases is largely symptomatic, and it does not bring satisfactory therapeutic effects. Today, there is a crucial need to design strategies for new drug development based on a better understanding of the biochemical mechanisms underlying the pathological conditions and on molecular targeting of therapeutic molecules based thereupon. Experimental and clinical observations reveal that nonselective, multipotent drugs appear to be more effective. According to the most recent trends, we should apply therapeutic tools which will simultaneously affect various systems (dual targeting drugs, multitargeting drugs).

In this Special Issue, original papers and reviews on neurodegenerative diseases, mental diseases, addictions or cancer as well as molecular targets involved in these diseases are welcome. Covered topics include (but are not limited to) the search for new active compounds (medicines) along with pharmacological and pharmacokinetic evaluation. All preclinical (in vitro, ex vivo, and in vivo tests) as well as clinical studies for the prevention or treatment of CNS diseases are invited.

Dr. Dorota Łażewska

Dr. Anna Stasiak

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

Pharmaceutics Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma